Iqbal S. Grewal, Ph.D., is a well-established scientist and biotechnologist with many years of research in immunology and oncology. He has extensive experience in the discovery and development of innovative protein-based biotherapeutics in many disease areas. Some of Dr. Grewal’s findings have already helped to translate research into key drug candidates for the treatment of autoimmune diseases and cancers. Currently, he is serving as Vice President of Preclinical Therapeutics at Seattle Genetics and leading preclinical research for the development of monoclonal antibodies and antibody-drug conjugates as therapeutics in the areas of autoimmunity and oncology.

• INTRODUCTION. Overview of Antibody-Based Therapeutics: Present and Future Promise. BIOLOGICS FOR AUTOIMMUNITY AND INFLAMMATION. Biologic Therapies for Multiple Sclerosis. Biologic Therapies in Rheumatoid Arthritis. Biologic Therapies in Systemic Lupus Erythematosus. Biologic Therapies for Inflammatory Bowel Disease. Biologic Therapies for Psoriasis. TNFa Inhibitors: Emerging Biologic Therapies for the Treatment of Asthma. Protein-Based Therapies in Experimental and Clinical Transplantation. Biologic Therapies for Type 1 Diabetes. BIOLOGICS FOR HEMATOLOGICAL MALIGNANCIES. Biologic Therapies for Acute Myeloid Leukemia/Myelodysplastic Syndrome. Biologic Therapies for Non-Hodgkin Lymphoma and Hodgkin Disease. Biologic Therapies for Chronic Lymphocytic Leukemia. Biologic Therapies for Multiple Myeloma and Plasma Cell Disorders. DEVELOPMENT OF BIOTHERAPIES FOR SOLID TUMORS. Antibody-Based Therapies for Carcinomas. Role of Vascular Targeting Agents in the Treatment of Solid Tumors: Current and Future Developments. Recent Advancements in the Use of Antibody–Drug Conjugates for Cancer Therapy. INDEX.

Select Guide Rating

Iqbal S. Grewal, Ph.D., is a well-established scientist and biotechnologist with many years of research in immunology and oncology. He has extensive experience in the discovery and development of innovative protein-based biotherapeutics in many disease areas. Some of Dr. Grewal’s findings have already helped to translate research into key drug candidates for the treatment of autoimmune diseases and cancers. Currently, he is serving as Vice President of Preclinical Therapeutics at Seattle Genetics and leading preclinical research for the development of monoclonal antibodies and antibody-drug conjugates as therapeutics in the areas of autoimmunity and oncology.

• INTRODUCTION. Overview of Antibody-Based Therapeutics: Present and Future Promise. BIOLOGICS FOR AUTOIMMUNITY AND INFLAMMATION. Biologic Therapies for Multiple Sclerosis. Biologic Therapies in Rheumatoid Arthritis. Biologic Therapies in Systemic Lupus Erythematosus. Biologic Therapies for Inflammatory Bowel Disease. Biologic Therapies for Psoriasis. TNFa Inhibitors: Emerging Biologic Therapies for the Treatment of Asthma. Protein-Based Therapies in Experimental and Clinical Transplantation. Biologic Therapies for Type 1 Diabetes. BIOLOGICS FOR HEMATOLOGICAL MALIGNANCIES. Biologic Therapies for Acute Myeloid Leukemia/Myelodysplastic Syndrome. Biologic Therapies for Non-Hodgkin Lymphoma and Hodgkin Disease. Biologic Therapies for Chronic Lymphocytic Leukemia. Biologic Therapies for Multiple Myeloma and Plasma Cell Disorders. DEVELOPMENT OF BIOTHERAPIES FOR SOLID TUMORS. Antibody-Based Therapies for Carcinomas. Role of Vascular Targeting Agents in the Treatment of Solid Tumors: Current and Future Developments. Recent Advancements in the Use of Antibody–Drug Conjugates for Cancer Therapy. INDEX.

Select Guide Rating

Iqbal S. Grewal, Ph.D., is a well-established scientist and biotechnologist with many years of research in immunology and oncology. He has extensive experience in the discovery and development of innovative protein-based biotherapeutics in many disease areas. Some of Dr. Grewal’s findings have already helped to translate research into key drug candidates for the treatment of autoimmune diseases and cancers. Currently, he is serving as Vice President of Preclinical Therapeutics at Seattle Genetics and leading preclinical research for the development of monoclonal antibodies and antibody-drug conjugates as therapeutics in the areas of autoimmunity and oncology.

• INTRODUCTION. Overview of Antibody-Based Therapeutics: Present and Future Promise. BIOLOGICS FOR AUTOIMMUNITY AND INFLAMMATION. Biologic Therapies for Multiple Sclerosis. Biologic Therapies in Rheumatoid Arthritis. Biologic Therapies in Systemic Lupus Erythematosus. Biologic Therapies for Inflammatory Bowel Disease. Biologic Therapies for Psoriasis. TNFa Inhibitors: Emerging Biologic Therapies for the Treatment of Asthma. Protein-Based Therapies in Experimental and Clinical Transplantation. Biologic Therapies for Type 1 Diabetes. BIOLOGICS FOR HEMATOLOGICAL MALIGNANCIES. Biologic Therapies for Acute Myeloid Leukemia/Myelodysplastic Syndrome. Biologic Therapies for Non-Hodgkin Lymphoma and Hodgkin Disease. Biologic Therapies for Chronic Lymphocytic Leukemia. Biologic Therapies for Multiple Myeloma and Plasma Cell Disorders. DEVELOPMENT OF BIOTHERAPIES FOR SOLID TUMORS. Antibody-Based Therapies for Carcinomas. Role of Vascular Targeting Agents in the Treatment of Solid Tumors: Current and Future Developments. Recent Advancements in the Use of Antibody–Drug Conjugates for Cancer Therapy. INDEX.

Select Guide Rating